Compare Chevron Corp (CVX) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Cassava Sciences Inc — how do they compare? Chevron Corp trades at $210.2 (market cap $414.98B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Chevron Corp is far larger — about 10532.5× Cassava Sciences Inc's market cap, and Chevron Corp pays a 3.37% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and Cassava Sciences Inc for 37 Days on average.
| CVX | FLNA | |
|---|---|---|
Market Cap | $414.98B | $39.40M |
Volume | 7,575,112 | 759,018 |
Sector | Energy | Health |
52-Week High | $217.73 | $4.64 |
52-Week Low | $146.72 | $0.68 |
Typical Hold Time | 101 Days | 37 Days |
Enterprise Value | $443.52B | -$43.28M |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $211.605, up 1.92% today, with a neutral technical signal. The stock shows strong earnings beats in recent quarters, with Q2 2026 EPS of $6.06 exceeding the $5.55 estimate. Revenue for 2025 was $184.43B, though net income declined to $12.30B. Analyst consensus is bullish with a $208.31 price target and 62% buy ratings. Recent news highlights Chevron's $13.8B investment in Argentina's Vaca Muerta and geopolitical impacts on oil prices.
The outlook for CVX is supported by high oil prices and strategic investments, but risks include volatile energy markets and declining profit margins. Earnings growth and dividend stability remain key catalysts, though geopolitical tensions and operational execution pose challenges for sustained shareholder returns.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
